Valuation: BioNTech SE

Market Cap 20.24B 23.14B 18.67B 17.24B 32.71B 2,207B 33.26B 223B 87.59B 1,087B 86.87B 84.98B 3,737B P/E 2026 *
-18.2x
P/E 2027 * -17.9x
Enterprise Value 9.38B 10.73B 8.65B 7.99B 15.17B 1,023B 15.42B 103B 40.61B 504B 40.28B 39.4B 1,733B EV / Sales 2026 *
4.33x
EV / Sales 2027 * 4.91x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.60%
1 week-6.21%
Current month-1.68%
1 month+6.20%
3 months-4.20%
6 months-8.37%
Current year-3.90%
1 week 91.02
Extreme 91.02
95.89
1 month 88.58
Extreme 88.58
98.81
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
12/05Free

Executive/Senior Manager

22,655 0.0094%
12/05Free

Chief Operating Officer

22,655 0.0094%
12/05Free

Chief Financial Officer

33,982 0.0141%
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%-6.21%-19.69%-14.84% 23.14B
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
-4.16%+1.63%+70.58%+143.85% 12.37B
Average -1.02%-0.09%+55.93%+148.15% 25.36B
Weighted average by Cap. -1.07%-1.31%+55.80%+138.10%

Financials

2026 *2027 *
Net sales 2.17B 2.48B 2B 1.85B 3.5B 236B 3.56B 23.89B 9.38B 116B 9.31B 9.1B 400B 2.23B 2.55B 2.06B 1.9B 3.61B 243B 3.67B 24.58B 9.65B 120B 9.58B 9.37B 412B
Net income -1.05B -1.2B -967M -894M -1.7B -114B -1.72B -11.56B -4.54B -56.34B -4.5B -4.4B -194B -1.16B -1.33B -1.07B -992M -1.88B -127B -1.91B -12.84B -5.04B -62.56B -5B -4.89B -215B
Net Debt -10.85B -12.41B -10.01B -9.25B -17.55B -1,184B -17.84B -120B -46.98B -583B -46.59B -45.58B -2,004B -9.29B -10.62B -8.56B -7.91B -15.01B -1,012B -15.26B -102B -40.19B -499B -39.86B -38.99B -1,715B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
10/07/26 USD 91.49 -1.60% 551,755
09/07/26 USD 92.98 -0.59% 816,162
08/07/26 USD 93.53 -0.81% 686,516
07/07/26 USD 94.29 +0.38% 896,013
06/07/26 USD 93.93 -3.71% 784,942
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
80.03EUR
Average target price
106.79EUR
Spread / Average Target
+33.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock